NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $27.38 +0.57 (+2.13%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$27.50 +0.12 (+0.42%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Veracyte Stock (NASDAQ:VCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Veracyte alerts:Sign Up Key Stats Today's Range$26.52▼$27.6450-Day Range$26.39▼$32.2352-Week Range$19.73▼$47.32Volume3.60 million shsAverage Volume913,642 shsMarket Capitalization$2.14 billionP/E Ratio66.78Dividend YieldN/APrice Target$40.90Consensus RatingModerate Buy Company OverviewVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.Read More… Veracyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreVCYT MarketRank™: Veracyte scored higher than 69% of companies evaluated by MarketBeat, and ranked 322nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 3 research reports in the past 90 days.Read more about Veracyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth5.88% Earnings GrowthEarnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is 66.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is 66.78, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.69% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.08 Percentage of Shares Shorted7.69% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.88 News SentimentVeracyte has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Veracyte this week, compared to 7 articles on an average week.Search Interest1 people have searched for VCYT on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Stock News HeadlinesVeracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"June 29 at 3:47 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Consensus Target Price from AnalystsJune 26, 2025 | americanbankingnews.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last yearJune 20, 2025 | finance.yahoo.comCathie Wood’s ARK buys BWX stock, sells Adaptive BiotechJune 18, 2025 | investing.comVeracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved ProfitabilityJune 9, 2025 | msn.comCathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D SystemsJune 7, 2025 | benzinga.comInsider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)June 6, 2025 | gurufocus.comSee More Headlines VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $39.60 at the beginning of 2025. Since then, VCYT shares have decreased by 30.9% and is now trading at $27.38. View the best growth stocks for 2025 here. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.07. The biotechnology company earned $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a net margin of 7.13% and a trailing twelve-month return on equity of 6.14%. Read the conference call transcript. Does Veracyte have any subsidiaries? The following companies are subsidiaries of Veracyte: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings2/24/2025Today6/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealthcare Current SymbolNASDAQ:VCYT CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees790Year Founded2006Price Target and Rating Average Stock Price Target$40.90 High Stock Price Target$50.00 Low Stock Price Target$28.00 Potential Upside/Downside+49.4%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio66.78 Forward P/E Ratio40.26 P/E GrowthN/ANet Income$24.14 million Net Margins7.13% Pretax Margin7.57% Return on Equity6.14% Return on Assets5.60% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio4.78 Sales & Book Value Annual Sales$445.76 million Price / Sales4.81 Cash Flow$1.04 per share Price / Cash Flow26.41 Book Value$15.17 per share Price / Book1.80Miscellaneous Outstanding Shares78,320,000Free Float77,219,000Market Cap$2.14 billion OptionableOptionable Beta2.10 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:VCYT) was last updated on 6/30/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.